Ann: GENERAL: PEB: PE Receives NZTE Support for Push into South East Asia

• Release Date: 12/08/15 17:09
• Summary: GENERAL: PEB: PE Receives NZTE Support for Push into South East Asia
• Price Sensitive: No
• Download Document  4.91KB

					PEB
12/08/2015 17:09
GENERAL
NOT PRICE SENSITIVE
REL: 1709 HRS Pacific Edge Limited

GENERAL: PEB: PE Receives NZTE Support for Push into South East Asia

12 August 2015

Pacific Edge Receives NZTE Support for Push into South East Asia

Cancer diagnostics company, Pacific Edge (NZX:PEB) has received another boost
to its plans to expand its global footprint, with a three-year $600,000 grant
from New Zealand Trade and Enterprise (NZTE).

The grant is milestone driven for investment over a three year period and
will aid in the evaluation of the South East Asia market opportunity for
Pacific Edge and its novel Cxbladder bladder cancer diagnostic tests, as well
as commercialisation and rollout into the region.  The grant funding requires
a matching investment by Pacific Edge. The company has already made good
progress in its initial investigations into South East Asia, with the launch
of a User Programme with the prestigious Tan Tock Seng hospital in Singapore
earlier this year.

Chief Executive Officer of Pacific Edge, David Darling, said: "We are pleased
with this vote of confidence  and have been working extensively with the NZTE
team in New Zealand and Singapore in our early evaluations. We are looking
forward to completing the evaluation of this opportunity and expanding our
footprint into South East Asia. This will be fantastic for our business and
leverages the laboratory in Dunedin and the technology that allows the urine
sample to be sent effectively over night from Singapore to Dunedin. Our
business model enables us to operate with a very small commercial footprint
and to service some great customers from New Zealand."

"We have identified South East Asia as offering exciting potential, with two
distinct customer segments of interest. Firstly are patients requiring
testing and management for bladder cancer, in the same way as our other
markets. Secondly and more unique to South East Asia, is the rapidly growing
number of medical tourists who come to the region for regular wellness and
medical checkups, where our Cxbladder tests could be a part of a variety of
tests offered to patients seeking an annual wellness regime".

"Logistically and commercially, Singapore is a great gateway to the markets
of South East Asia. It offers a number of benefits, including the widespread
use of English, internationally certified hospitals and a significant and
growing population of medical tourists supported by a strong commercial drive
in these countries to build businesses of scale to meet their needs, says
Brent Pownall, Commercial Director of Pacific Edge Diagnostics NZ Ltd.

"Other potential market opportunities in the region include Bangkok and
Taipei, which are also popular destinations for medical tourists."

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

GENERAL OVERVIEW

www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and monitoring of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies.

PRODUCTS

Pacific Edge has two proprietary, novel, accurate, molecular diagnostic
products in-market providing more accurate, and better detection and
management of urothelial cancer. Cxbladder Detect is available through the
company's dedicated CLIA certified laboratories for customers in New Zealand,
Australia and the USA. Cxbladder Triage is available in New Zealand and
Australia and will launch in the USA in 2015.

ABOUT Cxbladder Triage

www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with extra
phenotypic and clinical risk factors to accurately identify and remove
patients with haematuria who have a low probability of bladder cancer, from
requiring a full-urological work-up. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation and is intended to reduce of
the number of patients needing an expensive and invasive work-up for
urothelial cancer.

ABOUT Cxbladder Detect

www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.

Refer to www.cxbladder.com for more information.
End CA:00268316 For:PEB    Type:GENERAL    Time:2015-08-12 17:09:12